JoelNealMaslowMDPhD MBA FACP

Infectious Disease • Blue Bell, PA

HIV/AIDS Medicine, Mycobacterial Disease

Chief, Division of Infectious Diseases

Join to view full profile

Dr. Maslow is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Maslow's full profile

Already have an account?

Office
1040 Dekalb Pike
Suite 200
Blue Bell, PA 19422

Education & Training

Boston University Medical CenterFellowship, Infectious Disease, 1988 - 1991
Abington Memorial HospitalResidency, Internal Medicine, 1985 - 1988
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHInternship, Internal Medicine, 1984 - 1985
Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1984

Certifications & Licensure

NJ State Medical License 2012 - 2025
PA State Medical License 1985 - 2022
MI State Medical License 2011 - 2013
MA State Medical License 1988 - 1999
American Board of Internal Medicine Internal Medicine

Clinical Trials

GLS-5700 in Healthy Volunteers Start of enrollment: 2016 Jul 01
Completed
Phase 1
Evaluate the Safety, Tolerability and Immunogenicity Study of GLS-5300 in Healthy Volunteers Start of enrollment: 2018 Aug 28
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

1 citations
Immune response enhancement with GLS-5310 DNA primary vaccine against SARS-CoV-2 followed by administration of an mRNA vaccine heterologous boost.
Woo Joo Kim, Christine C Roberts, Joon Young Song, Jin Gu Yoon, Hye Seong
Vaccine. 2023-06-29
3 citations
Safety and immunogenicity of the bi-cistronic GLS-5310 COVID-19 DNA vaccine delivered with the GeneDerm suction device.
Woo Joo Kim, Christine C Roberts, Joon Young Song, Jin Gu Yoon, Hye Seong
International Journal of Infectious Diseases. 2023-03-01
14 citations
IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses.
Ji Won Han, Pil Soo Sung, Seon Hui Hong, Ho-Young Lee, June Young Koh
Journal of Hepatology. 2020-07-01

Press Mentions

GeneOne Life Science to Begin Phase 2 Clinical Trial of COVID-19 Pill in KoreaSeptember 9th, 2021
Letter from the EditorOctober 23rd, 2019
Tolerability of Intramuscular and Intradermal Delivery by CELLECTRA® Adaptive Constant Current Electroporation Device in Healthy VolunteersJune 4th, 2019